Table 2.

Adjusted Overall Survival, cT1–4c, cN1–3 Invasive Lobular Carcinoma Patients, National Cancer Data Base, 2004–2013 (N=12,312)

	HR (95% CI)	P-Value	Overall P-Value
Treatment group			<0.001
ACT	REF
NACT	1.38 (1.25 – 1.52)	<0.001
Age (years)			<0.001
≥50	REF
<50	0.73 (0.66 – 0.81)	<0.001
Race			<0.001
White	REF
Black	1.25 (1.09 – 1.43)	<0.001
Other	0.68 (0.51 – 0.93)	0.01
Ethnicity			<0.001
Hispanic	REF
Non-Hispanic	1.43 (1.16 – 1.78)	<0.001
Charlson/Deyo comorbidity score			<0.001
0	REF
1	1.26 (1.13 – 1.42)	<0.001
≥2	1.41 (1.10 – 1.81)	0.006
Clinical T stage			<0.001
1	REF
2	1.29 (1.137 – 1.47)	<0.001
3	1.55 (1.35 – 1.77)	<0.001
4	2.26 (1.88 – 2.71)	<0.001
Clinical N stage			<0.001
1	REF
2	1.24 (1.11 – 1.38)	<0.001
3	1.95 (1.72 – 2.21)	<0.001
Grade			<0.001
1	REF
2	1.24 (1.09 – 1.42)	0.002
3	1.69 (1.46 – 1.96)	<0.001
Treated with radiation post-lumpectomy			0.002
No	REF
Yes	0.66 (0.51 – 0.86)	0.002
Treated with endocrine therapy			<0.001
No	REF
Yes	0.75 (0.67 – 0.84)	<0.001

Hazard ratios (HRs), confidence intervals (CIs), and p-values are from a Cox proportional hazards model, stratified by year of diagnosis (grouped as 2004–2009 and 2010–2013) and hormone receptor status (positive/negative). A robust sandwich covariance estimator was used to account for correlation of patients treated at the same facility. Other covariates for which HRs are not shown include Surgery type, Treatment with radiation post-mastectomy, Income level, Education level, and Facility Type (all non-significant) as well as Facility location (p<0.001).

ACT: adjuvant chemotherapy. NACT: neoadjuvant chemotherapy.